Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025

Keros Therapeutics, Inc.

Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.
Company expects to complete enrollment by end of September 2024.
Topline data now expected in Q2 2025, earlier than previously anticipated.
CEO Jasbir Seehra cited strong demand and rapid enrollment as catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.